NCT00004161View on ClinicalTrials.gov

Fenretinide in Treating Patients With Leukoplakia of the Mouth

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 1997

Primary Completion Date

January 31, 2004

Study Completion Date

January 31, 2004

Conditions
Head and Neck Cancer
Interventions
DRUG

fenretinide

DRUG

Placebo

Trial Locations (1)

35294

University of Alabama Comprehensive Cancer Center, Birmingham

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Alabama at Birmingham

OTHER

NCT00004161 - Fenretinide in Treating Patients With Leukoplakia of the Mouth | Biotech Hunter | Biotech Hunter